NLS Pharmaceutics AGNASDAQ: NLSP

NLS Pharmaceutics (NASDAQ: NLSP ) stock is down on Thursday but that's only after the clinical-stage biopharmaceutical company's shares underwent a massive rally on Tuesday. Shares of NLSP stock closed out Tuesday, the prior day of trading due to the Juneteenth holiday on Wednesday, up 82.1%.

NLS Pharmaceutics (NASDAQ: NLSP ) stock is taking a beating on Monday as the company's shares come down from a rally on Friday. The news that sent shares of NLSP stock higher on Friday concerned an exclusive option to license in-license Aexon Labs' Dual Orexin Receptor Agonists platform.

Shares of NLS Pharmaceutics Ltd. NLSP, +19.57% gained 12% premarket on Monday after the Swiss clinical-stage biopharma company said it would proceed with phase 3 clinical studies of Mazindol ER, a treatment for narcolepsy.

NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET ZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced it will postpone its webcast previously scheduled for today due to important developments impacting the timing of the company update.

Presentation to take place on Tuesday, June 20, 2023, at 10:30AM ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20, 2023, at 10:30 AM ET.

Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic R&D progress and platform, including: Feedback from the SLEEP 2023 APSS Conference Initiation of the Phase 3 program AMAZE for Mazindol ER Pipeline Goals for 2023/2024 Key Financials Funding Strategy Update Corporate Development Webcast Information The event will be held June 30, 2023, at 11:00 am ET and will include a video stream on the Investors section of the Company's website here or at the SummitCast event page here.